A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Identifieur interne : 003548 ( Main/Exploration ); précédent : 003547; suivant : 003549A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Auteurs : Toru Hirano [Japon] ; Nobuyuki Ohguro ; Satoshi Hohki ; Keisuke Hagihara ; Yoshihito Shima ; Masashi Narazaki ; Atsushi Ogata ; Kazuyuki Yoshizaki ; Atsushi Kumanogoh ; Tadamitsu Kishimoto ; Toshio TanakaSource :
- Modern rheumatology [ 1439-7609 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Association de médicaments, Ciclosporine (usage thérapeutique), Colchicine (usage thérapeutique), Facteurs immunologiques (usage thérapeutique), Femelle, Humains, Induction de rémission, Infliximab, Maladie de Behçet (anatomopathologie), Maladie de Behçet (traitement médicamenteux), Prednisolone (usage thérapeutique), Récepteurs à l'interleukine-6 (immunologie), Échec thérapeutique, Études de suivi.
- MESH :
- anatomopathologie : Maladie de Behçet.
- immunologie : Récepteurs à l'interleukine-6.
- traitement médicamenteux : Maladie de Behçet.
- usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Ciclosporine, Colchicine, Facteurs immunologiques, Prednisolone.
- Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Induction de rémission, Infliximab, Échec thérapeutique, Études de suivi.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Behcet Syndrome (drug therapy), Behcet Syndrome (pathology), Colchicine (therapeutic use), Cyclosporine (therapeutic use), Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Immunologic Factors (therapeutic use), Infliximab, Middle Aged, Prednisolone (therapeutic use), Receptors, Interleukin-6 (immunology), Remission Induction, Treatment Failure.
- MESH :
- chemical , immunology : Receptors, Interleukin-6.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Colchicine, Cyclosporine, Immunologic Factors, Prednisolone.
- drug therapy : Behcet Syndrome.
- pathology : Behcet Syndrome.
- Adult, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Infliximab, Middle Aged, Remission Induction, Treatment Failure.
Abstract
A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.
DOI: 10.1007/s10165-011-0497-5
PubMed: 21748365
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A17
- to stream PubMed, to step Curation: 001A17
- to stream PubMed, to step Checkpoint: 001811
- to stream Ncbi, to step Merge: 000414
- to stream Ncbi, to step Curation: 000414
- to stream Ncbi, to step Checkpoint: 000414
- to stream Main, to step Merge: 003574
- to stream Main, to step Curation: 003548
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.</title><author><name sortKey="Hirano, Toru" sort="Hirano, Toru" uniqKey="Hirano T" first="Toru" last="Hirano">Toru Hirano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871</wicri:regionArea><wicri:noRegion>Osaka 565-0871</wicri:noRegion></affiliation></author><author><name sortKey="Ohguro, Nobuyuki" sort="Ohguro, Nobuyuki" uniqKey="Ohguro N" first="Nobuyuki" last="Ohguro">Nobuyuki Ohguro</name></author><author><name sortKey="Hohki, Satoshi" sort="Hohki, Satoshi" uniqKey="Hohki S" first="Satoshi" last="Hohki">Satoshi Hohki</name></author><author><name sortKey="Hagihara, Keisuke" sort="Hagihara, Keisuke" uniqKey="Hagihara K" first="Keisuke" last="Hagihara">Keisuke Hagihara</name></author><author><name sortKey="Shima, Yoshihito" sort="Shima, Yoshihito" uniqKey="Shima Y" first="Yoshihito" last="Shima">Yoshihito Shima</name></author><author><name sortKey="Narazaki, Masashi" sort="Narazaki, Masashi" uniqKey="Narazaki M" first="Masashi" last="Narazaki">Masashi Narazaki</name></author><author><name sortKey="Ogata, Atsushi" sort="Ogata, Atsushi" uniqKey="Ogata A" first="Atsushi" last="Ogata">Atsushi Ogata</name></author><author><name sortKey="Yoshizaki, Kazuyuki" sort="Yoshizaki, Kazuyuki" uniqKey="Yoshizaki K" first="Kazuyuki" last="Yoshizaki">Kazuyuki Yoshizaki</name></author><author><name sortKey="Kumanogoh, Atsushi" sort="Kumanogoh, Atsushi" uniqKey="Kumanogoh A" first="Atsushi" last="Kumanogoh">Atsushi Kumanogoh</name></author><author><name sortKey="Kishimoto, Tadamitsu" sort="Kishimoto, Tadamitsu" uniqKey="Kishimoto T" first="Tadamitsu" last="Kishimoto">Tadamitsu Kishimoto</name></author><author><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21748365</idno><idno type="pmid">21748365</idno><idno type="doi">10.1007/s10165-011-0497-5</idno><idno type="wicri:Area/PubMed/Corpus">001A17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A17</idno><idno type="wicri:Area/PubMed/Curation">001A17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A17</idno><idno type="wicri:Area/PubMed/Checkpoint">001811</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001811</idno><idno type="wicri:Area/Ncbi/Merge">000414</idno><idno type="wicri:Area/Ncbi/Curation">000414</idno><idno type="wicri:Area/Ncbi/Checkpoint">000414</idno><idno type="wicri:Area/Main/Merge">003574</idno><idno type="wicri:Area/Main/Curation">003548</idno><idno type="wicri:Area/Main/Exploration">003548</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.</title><author><name sortKey="Hirano, Toru" sort="Hirano, Toru" uniqKey="Hirano T" first="Toru" last="Hirano">Toru Hirano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871</wicri:regionArea><wicri:noRegion>Osaka 565-0871</wicri:noRegion></affiliation></author><author><name sortKey="Ohguro, Nobuyuki" sort="Ohguro, Nobuyuki" uniqKey="Ohguro N" first="Nobuyuki" last="Ohguro">Nobuyuki Ohguro</name></author><author><name sortKey="Hohki, Satoshi" sort="Hohki, Satoshi" uniqKey="Hohki S" first="Satoshi" last="Hohki">Satoshi Hohki</name></author><author><name sortKey="Hagihara, Keisuke" sort="Hagihara, Keisuke" uniqKey="Hagihara K" first="Keisuke" last="Hagihara">Keisuke Hagihara</name></author><author><name sortKey="Shima, Yoshihito" sort="Shima, Yoshihito" uniqKey="Shima Y" first="Yoshihito" last="Shima">Yoshihito Shima</name></author><author><name sortKey="Narazaki, Masashi" sort="Narazaki, Masashi" uniqKey="Narazaki M" first="Masashi" last="Narazaki">Masashi Narazaki</name></author><author><name sortKey="Ogata, Atsushi" sort="Ogata, Atsushi" uniqKey="Ogata A" first="Atsushi" last="Ogata">Atsushi Ogata</name></author><author><name sortKey="Yoshizaki, Kazuyuki" sort="Yoshizaki, Kazuyuki" uniqKey="Yoshizaki K" first="Kazuyuki" last="Yoshizaki">Kazuyuki Yoshizaki</name></author><author><name sortKey="Kumanogoh, Atsushi" sort="Kumanogoh, Atsushi" uniqKey="Kumanogoh A" first="Atsushi" last="Kumanogoh">Atsushi Kumanogoh</name></author><author><name sortKey="Kishimoto, Tadamitsu" sort="Kishimoto, Tadamitsu" uniqKey="Kishimoto T" first="Tadamitsu" last="Kishimoto">Tadamitsu Kishimoto</name></author><author><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name></author></analytic><series><title level="j">Modern rheumatology</title><idno type="eISSN">1439-7609</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Behcet Syndrome (drug therapy)</term><term>Behcet Syndrome (pathology)</term><term>Colchicine (therapeutic use)</term><term>Cyclosporine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunologic Factors (therapeutic use)</term><term>Infliximab</term><term>Middle Aged</term><term>Prednisolone (therapeutic use)</term><term>Receptors, Interleukin-6 (immunology)</term><term>Remission Induction</term><term>Treatment Failure</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Association de médicaments</term><term>Ciclosporine (usage thérapeutique)</term><term>Colchicine (usage thérapeutique)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Infliximab</term><term>Maladie de Behçet (anatomopathologie)</term><term>Maladie de Behçet (traitement médicamenteux)</term><term>Prednisolone (usage thérapeutique)</term><term>Récepteurs à l'interleukine-6 (immunologie)</term><term>Échec thérapeutique</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Receptors, Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Colchicine</term><term>Cyclosporine</term><term>Immunologic Factors</term><term>Prednisolone</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Maladie de Behçet</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Behcet Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Récepteurs à l'interleukine-6</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Behcet Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Behçet</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Ciclosporine</term><term>Colchicine</term><term>Facteurs immunologiques</term><term>Prednisolone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infliximab</term><term>Middle Aged</term><term>Remission Induction</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Infliximab</term><term>Échec thérapeutique</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Hagihara, Keisuke" sort="Hagihara, Keisuke" uniqKey="Hagihara K" first="Keisuke" last="Hagihara">Keisuke Hagihara</name><name sortKey="Hohki, Satoshi" sort="Hohki, Satoshi" uniqKey="Hohki S" first="Satoshi" last="Hohki">Satoshi Hohki</name><name sortKey="Kishimoto, Tadamitsu" sort="Kishimoto, Tadamitsu" uniqKey="Kishimoto T" first="Tadamitsu" last="Kishimoto">Tadamitsu Kishimoto</name><name sortKey="Kumanogoh, Atsushi" sort="Kumanogoh, Atsushi" uniqKey="Kumanogoh A" first="Atsushi" last="Kumanogoh">Atsushi Kumanogoh</name><name sortKey="Narazaki, Masashi" sort="Narazaki, Masashi" uniqKey="Narazaki M" first="Masashi" last="Narazaki">Masashi Narazaki</name><name sortKey="Ogata, Atsushi" sort="Ogata, Atsushi" uniqKey="Ogata A" first="Atsushi" last="Ogata">Atsushi Ogata</name><name sortKey="Ohguro, Nobuyuki" sort="Ohguro, Nobuyuki" uniqKey="Ohguro N" first="Nobuyuki" last="Ohguro">Nobuyuki Ohguro</name><name sortKey="Shima, Yoshihito" sort="Shima, Yoshihito" uniqKey="Shima Y" first="Yoshihito" last="Shima">Yoshihito Shima</name><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name><name sortKey="Yoshizaki, Kazuyuki" sort="Yoshizaki, Kazuyuki" uniqKey="Yoshizaki K" first="Kazuyuki" last="Yoshizaki">Kazuyuki Yoshizaki</name></noCountry><country name="Japon"><noRegion><name sortKey="Hirano, Toru" sort="Hirano, Toru" uniqKey="Hirano T" first="Toru" last="Hirano">Toru Hirano</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003548 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003548 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21748365
|texte= A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21748365" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |